Hypothalamic Obesity (HO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Hypothalamic obesity (HO) is a severe and heterogeneous disease related to several conditions, such as hypothalamic damage caused by tumors and/or their treatment, inflammatory, trauma, neurosurgery, cerebral aneurysm, single-gene mutations (e.g., leptin, leptin receptor, CART, POMC), rare congenital disorders with midline, genetic syndromes, and the use of psychotropic drugs. The weight gain pattern in HO patients is characterized by a sudden onset and rapid acceleration after hypothalamic damage. The symptoms of hypothalamic obesity vary by the cause and include uncontrollable hunger, rapid, excessive weight gain, and a low metabolic rate. If the pituitary gland is involved, symptoms may include small underdeveloped testes in males and delayed puberty. This condition most often occurs because of injury to the hypothalamus due to a tumor, swelling in the brain, brain surgery, or head trauma. · The most common causes of acquired hypothalamic damage are space-occupying lesions, s